Tural 2002.

Methods	A randomized open‐label multi‐centre factorial design trial at 13 hospitals in 10 cities in Spain
Participants	326 participants Inclusion: plasma RNA > 1000 copies/mL, on stable ART combination for longer than 6 months Exclusion: substantial antiretroviral‐related adverse events history, poor adherence or active drug abuse reported by the treating physician
Interventions	Intervention 1: genotyping without expert advice (G+/EA‐) Intervention 2: genotyping and expert advice (G+/EA+) Intervention 3: no genotyping with expert advice (G‐/EA+) Control: no genotyping and no expert advice (G‐/EA‐)
Outcomes	Virological success (< 400 copies/mL), change in viral load
Notes	All participants provided informed consent. Funding: Visible Genetics Trial acronym: Havana
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomization was not reported.
Allocation concealment (selection bias)	Low risk	Central location randomization was conducted.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	This was an open‐label study (knowledge of allocation is unlikely to introduce bias).
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Trial authors did not report this information (knowledge of allocation is unlikely to introduce bias).
Incomplete outcome data (attrition bias) All outcomes	Low risk	Losses to follow‐up were balanced between groups. Trial authors performed ITT analyses.
Selective reporting (reporting bias)	Low risk	All relevant outcomes were reported.
Other bias	Low risk	We found no other sources of bias.
Overall risk assessment	Low risk	We had no serious risk of bias concerns.